Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension -

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Renal and urologic disorders
Summary
This RCT (n=196) reports at week 52, more patients on veverimer vs placebo had an increase in bicarbonate (≥4 mmol/L or normalisation, 63% vs 38%, p=0.0015) and higher bicarbonate concentrations were observed at all time-points starting at week 1 (p<0.001).
UKMi comment

Veverimer is a non-absorbed, orally-administered polymer currently in phase III development.

In a related editorial, authors comment that in future studies, comparison of veverimer to currently available/approved treatments will be essential, particularly examining any superiority of veverimer related to safety, clinical outcome, and side-effects. This comparison is especially important given the probable large difference in cost between the new agent and these other treatments (such as sodium bicarbonate, sodium or potassium citrate).
Related links: Comment